Ono Pharmaceutical reports results of Deciphera acquisition

Ono Pharmaceutical (OPHLY) has successfully completed the tender offer to acquire all outstanding shares of common stock of Deciphera Pharmaceuticals (DCPH) for $25.60 per share – total amount of approximately $2.4B -, through its wholly owned subsidiary, Topaz Merger Sub. On June 11, following the completion of the tender offer, Merger Sub merged with and into Deciphera with Deciphera continuing as the surviving corporation and a wholly owned subsidiary of Ono. In connection with the acquisition, Deciphera shares ceased to be traded on Nasdaq as of the date of closing of the acquisition and shares of Deciphera’s common stock will be delisted from Nasdaq.